Desirudin
A Summary of Recent Data in Patients With or at Risk for Heparin-Induced Thrombocytopenia

Jerrold H. Levy, MD, FAHA
Department of Anesthesiology and Critical Care
Emory University School of Medicine and Emory Healthcare
Atlanta, Georgia

Jeanine M. Walenga, PhD
Cardiovascular Institute
Loyola University Medical Center
Maywood, Illinois
Desirudin: A Summary of Recent Data in Patients With or at Risk for HIT

Faculty And Unapproved Use Disclosures

All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed at the beginning of each activity. The faculty of this educational activity discloses the following:

- **Dr Levy** reports that he served as a member of the steering committee for Canyon Pharmaceuticals.
- **Dr Walenga** reports that she has no relevant conflicts to disclose.

This research was financially sponsored by Canyon Pharmaceuticals. Medical writing support was provided by Michael Morren, RPh, of Peloton Advantage, LLC, and was financially sponsored by Canyon Pharmaceuticals.
Desirudin: A Summary of Recent Data in Patients With or at Risk for Heparin-Induced Thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is a life-threatening, prothrombotic, immune-mediated coagulopathy caused by antibodies that bind to macromolecular complexes of heparin and platelet factor 4 (PF4). The antibody-mediated platelet activation that occurs as PF4 binds to heparin releases prothrombotic microparticles.

HIT can occur with any route of heparin administration. According to the current American College of Chest Physicians Guidelines for treatment and prevention of HIT, thrombocytopenia in HIT is defined as a fall in the platelet count of more than 50%, occurring 5 to 14 days after beginning heparin therapy, although it may occur earlier in some patients with previous occult exposure. In other patients (3%–5%), thrombocytopenia does not begin to occur until several days after heparin therapy has been discontinued.

Incidence of HIT
An estimated 8% to 50% of patients treated with heparin develop heparin/PF4 antibodies, and HIT occurs in approximately 0.2% to 5.0% of heparin-treated patients. The incidence of HIT depends on the heparin preparation (unfractionated heparin [UFH] > low-molecular-weight heparin [LMWH]), the patient population type (eg, postsurgery, medical, pregnant), whether patients are critically ill, the duration of heparin exposure, and sex.

The patient groups at highest risk for HIT (≥1%) include postoperative, cardiac, vascular, and percutaneous coronary intervention patients, who often have multiple exposures to heparin, receive high doses of heparin, or receive heparin for an extended period of time.

HIT is an important cause of hypercoagulability, and thrombotic complications develop in approximately 38% to 76% of patients. This translates to an estimated 300,000 patients with HIT-related complications and 90,000 deaths per year in the United States.

Costs of Treatment
HIT is costly. Total annual costs in the United States when HIT complicates open-heart surgery are estimated at $300 million. An economic analysis from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry was conducted to assess the incremental impact of thrombocytopenia on in-hospital costs among 1,988 patients receiving heparin for at least 96 hours. Thrombocytopenia was defined as (1) an absolute reduction in platelet count of less than 150 x 10^9/L (n=353), (2) a relative reduction in platelet count of more than 50% from admission levels (n=41), or (3) meeting both criteria (n=185). Patients in all three categories had significantly longer hospital stays and greater medical costs than did the group without thrombocytopenia. The differential was greatest in the thrombocytopenia group that met both criteria. In that group, the average length of hospital stay was 22.3 days, and average hospital costs were $61,760, compared with 13.0 days and $23,154 for patients without thrombocytopenia (P<0.001).

Diagnosis of HIT
Diagnosis is based on both clinical and serologic findings. Thrombocytopenia or thrombosis and heparin-dependent antibodies are needed to confirm the diagnosis. Clinical suspicion of HIT should arise when any of the following occurs in association with the presence of heparin-dependent antibodies: (1) an otherwise unexplained platelet count fall of at least 30% to 50%, even if the platelet count nadir remains above 150 x 10^9/L; (2) venous or arterial thrombosis; (3) skin lesions at heparin injection sites; or (4) acute systemic reactions (eg, fever/chills, tachycardia, hypertension, dyspnea, cardiopulmonary arrest) that occur after intravenous (IV) heparin bolus administration.

The diagnosis of HIT can often be challenging, given the frequent use of heparin and the common occurrence of thrombocytopenia arising from other causes in the hospital setting, such as perioperative hemodilution, multiorgan dysfunction syndrome, sepsis, and immune-mediated thrombocytopenia caused by other medications (eg, quinidine, rifampin, vancomycin, and sulfas antibiotics). Nonpathogenic heparin/PF4-reactive antibodies frequently occur in patients who have recently received heparin; a positive test for heparin-dependent antibodies does not necessarily mean that a patient has HIT.
Novel data on the use of desirudin in various patient populations with confirmed or suspected HIT were recently presented at several medical society meetings and are summarized here.

### Overview of the PREVENT-HIT Study

The PREVENT-HIT trial was an open-label, exploratory study designed to assess the clinical and economic utility of a twice-daily fixed dose of SC desirudin given to prevent thrombosis in critically ill patients with suspected HIT (with or without thrombosis), compared with a continuous infusion of aPTT-adjusted argatroban. The details of the methodology and results of this study were recently reported and are briefly summarized here.

Sixteen adult patients in whom HIT was clinically suspected were randomized to one of two treatment arms (group A or B). Eight patients who had not previously received treatment with a DTI were assigned to group A; of these, four patients received desirudin, and four patients received argatroban. Group B included eight patients who were already being treated with argatroban before study entry. Of these, four patients continued to receive argatroban, and four patients were randomized to desirudin.

Patients assigned to desirudin who did not have clinical evidence of thrombosis received 15 mg SC every 12 hours (n=7); those with thrombosis at study entry received desirudin 30 mg SC every 12 hours (n=1). Argatroban was administered via IV infusion and titrated to a therapeutic aPTT according to the standard of care at each study center. Patients were transitioned to warfarin once their platelet counts exceeded 100 to 150 x 10^9/L. The main efficacy measure was the composite of new-onset or worsening thrombosis requiring discontinuation of study medication, amputation, or all-cause mortality up to 30 days after discontinuation of study medication. Descriptive statistics were used to describe all data collected. Incidence of major and minor bleeding and of pharmacoeconomic outcomes was also assessed. Major bleeding was defined as a fall in hemoglobin of more than 2 g/dL requiring transfusion; all other bleeding was classified as minor. One patient in group B receiving desirudin withdrew consent and discontinued participation on day 5 of treatment, but all 16 patients were included in efficacy and safety analyses.

Patient demographics and baseline characteristics for the overall population and for the subgroup with

### TABLE 1. PREVENT-HIT Patient Demographics and Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>OVERALL COHORT</th>
<th>CONFIRMED HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Desirudin (n=8)</td>
<td>Argatroban (n=8)</td>
</tr>
<tr>
<td>Mean age, years ± SD (Q1, Q3)</td>
<td>69.0 ± 9.5 (62, 76)</td>
<td>62.0 ± 9.3 (63, 70)</td>
</tr>
<tr>
<td>Gender male, n</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Mean weight, kg ± SD (Q1, Q3)</td>
<td>81± 22 (64, 96)</td>
<td>100 ± 37 (84, 130)</td>
</tr>
<tr>
<td>Baseline platelet count x10^9/L ± SD (Q1, Q3)</td>
<td>88 ± 40 (63, 124)</td>
<td>121 ± 68 (84, 137)</td>
</tr>
<tr>
<td>Renal function, ClCR ± SD (Q1, Q3)</td>
<td>50 ± 19 (37, 64)</td>
<td>58 ± 25 (42, 77)</td>
</tr>
<tr>
<td>Moderate or severe renal impairment, n</td>
<td>5</td>
<td>4</td>
</tr>
</tbody>
</table>

ClCR=creatinine clearance measured in milliliters per minute, Q1=quartile 1, Q3=quartile 3.

Source: Boysie et al^21
confirmed HIT are summarized in Table 1 on page 4. Renal impairment was defined as creatinine clearance (CLcr) below 60 mL/min. On average, patients assigned to desirudin were older, had lower body weight, and had a lower platelet count at baseline than patients treated with argatroban. In the primary analysis, no differences were observed in thrombotic outcomes or in the incidence of bleeding between desirudin and argatroban.

**PREVENT-HIT Renal Impairment Subanalysis**

Desirudin is primarily eliminated via renal mechanisms.21,24 The current US Food and Drug Administration (FDA)-approved prescribing information for desirudin recommends a reduction in dosage from 15 mg SC every 12 hours to 5 mg SC every 12 hours in patients with moderate renal impairment (CLcr 39–59 mL/min/1.73 m²) and to 1.7 mg SC every 12 hours in patients with severe impairment (12.1–27.2 mL/min/1.73 m²).29 This recommendation is based on data from a single-dose IV study that compared total exposure (area under the curve [AUC]) in patients with renal impairment and in healthy volunteers.30 However, data from two recent analyses—one assessing clinical outcomes in total hip replacement and the steady-state pharmacokinetics of desirudin 15 mg SC every 12 hours for up to 6 days, and another evaluating clinical outcomes in patients with renal impairment undergoing major orthopedic surgery and treated with desirudin 15 mg twice daily or enoxaparin 40 mg daily—suggest that dose reduction of desirudin in patients with moderate renal impairment is not warranted.31,32 These data are being submitted to the FDA for review to determine if recommendations in the current prescribing information for patients with renal impairment should be modified. Since desirudin is eliminated by the kidneys, and renal impairment is common in critically ill patients, a subgroup analysis was performed on the PREVENT-HIT data set to evaluate the efficacy and safety of desirudin at standard fixed doses in patients with renal impairment.33 Median CLcr rates for the overall argatroban and desirudin groups, as well as the subgroup of patients with renal impairment who received desirudin, are shown in the left panel of Figure 1. Changes in aPTT levels in desirudin-treated patients stratified by CLcr are shown in the right panel.

Efficacy and safety outcomes for the overall desirudin and argatroban groups, and for the subgroup of patients with renal impairment treated with desirudin, are summarized in Table 2. Patients with moderate renal impairment (CLcr 30–60 mL/min) did not experience exaggerated increases in aPTT with fixed-dose desirudin, and moderate renal impairment was not associated with excess bleeding.

**PREVENT-HIT Health Economics Subanalysis**

Another analysis of the PREVENT-HIT data set was conducted to investigate differences in resource utilization and economic outcomes between the desirudin and argatroban treatment groups.34 A summary of medication costs, duration of treatment, and length of hospital stay for each treatment group is presented in Figure 2 on page 6.
Data on the transition from desirudin and argatroban to warfarin in patients with confirmed HIT is presented in FIGURE 3.

The mean cost of medication per course of treatment was $1,991 for desirudin and $10,230 for argatroban, with an average savings of $8,239 (range $2,288–$15,325) per patient treated with desirudin. Patients receiving desirudin had a shorter mean treatment (5.9 days) and a shorter mean postrandomization length of stay (9.4 days) than did patients treated with argatroban (9.3 and 16 days, respectively). Patients on desirudin who had confirmed HIT (n=5) required an average of 1.8 fewer days of warfarin overlap (4.6 days), compared with argatroban (n=6, 6.4 days). Patients with confirmed HIT and treated with desirudin who were transitioned to warfarin (n=5) had an average of 5.0 international normalized ratio (INR) tests compared with 8.7 INR tests for argatroban patients (n=7).

Perioperative Use of Desirudin in Patients With and Without HIT Undergoing Orthopedic Surgery: The DESIRE Registry

DVT is an important complication in patients undergoing major orthopedic surgery, and routine pharmacologic thrombosis prophylaxis is recommended for most patients in this setting. There are few alternatives to heparin-based anticoagulants for surgical patients who are not candidates for heparin therapy (eg, patients with HIT or a history of HIT). The Desirudin Post-Marketing Registry–Europe in Patients Undergoing Major Orthopedic Surgery (DESIRE Registry) was an observational, multicenter, single-arm registry that enrolled 603 patients undergoing major orthopedic surgery. All patients received desirudin 15 mg SC twice daily and were followed and evaluated for DVT, pulmonary embolism (PE), bleeding, and death throughout their hospital stay. Of the 581 patients included in the overall analysis, 303 (52.2%) underwent hip replacement, 196 (33.7%) total knee replacement, 39 (6.7%) hip-fracture repair, and 43 (7.4%) other types of surgery (eg, spinal or trauma). Patient characteristics are summarized in TABLE 3 on page 7. The mean duration of treatment with desirudin was 11 days; 28.3% of the patients received desirudin for more than 12 days. Desirudin was given prior to surgery in 50.3% of the patients and after surgery in 48.8% of the patients. A summary of clinical outcomes that occurred during hospitalization is presented in TABLE 4 on page 7.

A subanalysis of the DESIRE Registry that included 51 patients who had clinical HIT (n=14; 6 were confirmed with serology) or a history of HIT (n=47; 37 did not have HIT during the indexed period) evaluated the efficacy and safety of desirudin in this high-risk subset. Of the patients with clinical HIT, none died or experienced a thrombotic event; there was one reported major bleeding event, but cessation of desirudin treatment was not required. Of the patients with a history of HIT, one patient developed DVT after receiving 1 dose of desirudin, and
Perioperative Use of Desirudin in Patients With Heparin Antibodies Undergoing CABG

Results from previous observational studies suggest that antibodies to heparin/PF4 complexes are prevalent in patients undergoing cardiac surgery.34,39 In these studies, the presence of heparin/PF4 antibodies before surgery was a significant, independent risk factor for increased perioperative morbidity and mortality. Anticoagulation and VTE prophylaxis during the perioperative period, while avoiding heparin with the use of a DTI, may improve outcomes in these patients.

A prospective observational study was conducted to evaluate the efficacy and safety of desirudin in patients undergoing elective coronary artery bypass graft (CABG) surgery who were positive for heparin antibodies at baseline but had no clinical evidence of HIT.40 Desirudin 15 mg SC was administered twice daily preoperatively and postoperatively, for VTE prophylaxis. Bivalirudin IV was administered for anticoagulation during surgery. Outcomes measured included thrombosis, major bleeding, and development of clinical HIT.

A total of 28 patients were enrolled. Desirudin was administered to 18 patients preoperatively and to 24 patients postoperatively. On average, 3 doses of desirudin were given preoperatively, with the last dose given at 8:00 P.M. on the evening before surgery. Treatment with desirudin was reinitiated within 12 hours after surgery in three of the patients, within 12 to 24 hours in eight patients, and longer than 24 hours after surgery in seven patients. The results of this study are summarized in TABLE 5. One thrombotic event was reported, occurring about 30 days after the last dose of desirudin. No major bleeding events and no cases of clinical HIT were reported after surgery.

### TABLE 5. Results of the Desirudin Study in Patients With Heparin Antibodies Undergoing Coronary Artery Bypass Graft

<table>
<thead>
<tr>
<th>Patients (N=28)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with CLcr &lt;60 mL/min</td>
<td>14</td>
</tr>
<tr>
<td>Patients with CLcr &gt;60 mL/min</td>
<td>14</td>
</tr>
<tr>
<td>Patients with postoperative HIT</td>
<td>0</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>0</td>
</tr>
<tr>
<td>Thrombotic events</td>
<td>1</td>
</tr>
</tbody>
</table>

### Summary and Conclusions

Diagnosis of HIT can be challenging given the extensive use of heparin in the hospital setting and the common occurrence of thrombocytopenia due to other causes. Whenever there is a clinical suspicion or confirmed diagnosis of HIT, heparin should be discontinued immediately, and alternative methods of anticoagulation should be initiated pending laboratory confirmation.

DTIs are a mainstay of treatment for HIT. Argatroban has the broadest indication in the United States; it is approved for both prophylaxis and treatment of thrombosis in patients with HIT.41 However, it must be administered intravenously; must be closely monitored using aPTT or activated clotting time; has a substantial effect on INR, which may complicate the transition to oral therapy; and is costly.

Desirudin also exhibits predictable pharmacokinetics when administered at a fixed dose but does not require routine monitoring when it is given for thrombosis prophylaxis or treatment.29 It has less effect on INR than does argatroban and is the only DTI approved for SC injection. Based on the study results described here, desirudin may be a cost-effective alternative to argatroban. Further clinical studies in the setting of HIT are warranted.

### TABLE 3. DESIRE Registry: Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients (N=581)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years ± SD</td>
<td>67.9 ± 5.0</td>
</tr>
<tr>
<td>Mean duration of desirudin therapy, days ± SD</td>
<td>11 ± 6.6</td>
</tr>
<tr>
<td>BMI &gt;30 kg/m², %</td>
<td>30.0</td>
</tr>
<tr>
<td>Medical history, %</td>
<td></td>
</tr>
<tr>
<td>3 risk factors for DVT, not including orthopedic surgery</td>
<td>66.7</td>
</tr>
<tr>
<td>Prior DVT</td>
<td>35.0</td>
</tr>
<tr>
<td>Prior PE</td>
<td>9.8</td>
</tr>
<tr>
<td>Post-thrombotic syndrome</td>
<td>13.0</td>
</tr>
<tr>
<td>Malignancy</td>
<td>10.0</td>
</tr>
<tr>
<td>Diabetes</td>
<td>17.0</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>33.0</td>
</tr>
<tr>
<td>Tobacco usage</td>
<td>17.0</td>
</tr>
</tbody>
</table>

Six patients experienced major bleeding. Desirudin was not discontinued in any of these cases. The patient with DVT was switched to heparin for unknown reasons and 10 days later developed a symptomatic DVT confirmed with phlebography.

Few venous thrombotic events occurred in this population of orthopedic surgery patients, and the incidence of bleeding was low in the overall population. The incidence of bleeding was also low in the subgroup of patients with HIT. However, interpretation of the results is limited by the observational nature of the study.

It is important to note that all anticoagulant medications, including DTIs such as desirudin, are associated with an increased risk of bleeding and should be used cautiously.
References

40. Levy J, Koster A. Safety of perioperative bridging with desirudin and intraoperative bivalirudin in patients with heparin antibodies undergoing coronary artery bypass surgery (CABG) [abstract]. Presented at: 33rd Annual Meeting and Workshops of the Society of Cardiovascular Anesthesiologists; April 30-May 4, 2011; Savannah, GA.
42. Levy J, Kurz M, Whelton A. Lack of clinically significant interactions between the subcutaneously administered direct thrombin inhibitor desirudin and orally administered warfarin upon the international normalized ratio [abstract 22416]. Presented at: 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA.

8 | Desirudin: A Summary of Recent Data in Patients With or at Risk for HIT